This website has been designed to provide information about the Phase III clinical trial of Transferrin-CRM107 (Tf-CRM107, proposed trade name TransMID^TM), for the potential treatment of non-operable, progressive and/or recurrent glioblastoma multiforme, a type of brain cancer commonly referred to as GBM. This clinical trial is a research study designed to compare this investigational drug, Tf-CRM107, with the best standard of care treatment currently available.